bioMérieux Records 7.3% Organic Growth Over the First Nine Months of 2025
bioMérieux has announced a 7.3% increase in organic sales growth for the first nine months of the year, reaching 2,992 million euros, according to the press release.
According to information provided by bioMérieux, consolidated sales for the first nine months of 2025 reached 2,992 million euros, representing a growth of 4.2% compared to the same period last year, where sales amounted to 2,871 million euros. This increase includes an organic growth of 7.3%, although the impact of currency effects was negative, representing a decrease of 85 million euros. In terms of quarterly performance, the company observed an organic sales growth of 3% in the third quarter, affected by a double-digit decline in China and an 8% drop in sales of BIOFIRE® respiratory panels, a segment influenced by low epidemiological activity.
Expansion of Product Portfolio and Installed Base
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
bioMérieux continues to expand its installed base, particularly for its BIOFIRE® and SPOTFIRE® systems, which have shown growths of 9% and 114% respectively over the first nine months. The company also obtained FDA 510(k) clearance and CLIA waiver for its SPOTFIRE® R/ST Panel Mini test, thereby enhancing its diagnostic offerings. Additionally, bioMérieux launched GENE-UP® PRO HRM, a new quality control solution based on DNA detection of thermoresistant molds. These actions are part of the strategic plan GO•28 aimed at continuous profitability improvement.
2025 Forecasts Adjusted
bioMérieux has adjusted its forecasts for 2025, expecting an organic revenue growth between 5.5% and 6.5% at constant exchange rates, thus revising its previous forecasts downward due to a late respiratory season. However, the company maintains its growth forecasts for current contributory operating income (ROCC), which is expected to increase between 12% and 18%, also at constant exchange rates. Nevertheless, currency effects are expected to negatively impact annual CEBIT by 30 million euros. In terms of regions, North America and Latin America show positive dynamics, while Asia-Pacific, particularly China, records performance declines.
Dans un contexte de faible activité épidémiologique, nous continuons à faire croître notre base installée, en particulier pour BIOFIRE® et SPOTFIRE®, et à améliorer la rentabilité dans le cadre du plan GO•28.
Ventes consolidées de 2 992 millions d'euros sur 9 mois (+4,2 % publié, +7,3 % organique). Forte croissance des panels non-respiratoires et de SPOTFIRE (croissance organique 114 %), ralentissement en Chine et moindre épidémiologie respiratoire. Révision de la guidance organique 2025 à +5,5 % / +6,5 %; ROCC attendu +12 % / +18 %. Effet de change négatif -85 millions d'euros sur les ventes 9 mois et ~-30 millions d'euros attendu sur le CEBIT annuel.
Risks mentioned
faible activité épidémiologique impactant les ventes de panels respiratoires
recul significatif des ventes en Chine
risque de change défavorable (impact -85 millions d'euros sur 9 mois, ~-30 millions d'euros sur CEBIT attendu)
risques liés aux économies en hyperinflation (Argentine, Turquie)
Opportunities identified
forte dynamique de SPOTFIRE (base installée >5 500, +160 % sur 12 mois)
croissance des panels non-respiratoires BIOFIRE
développements de nouveaux produits (GENE-UP® PRO HRM) et lancements soutenant les applications industrielles
croissance robuste des Applications Industrielles, notamment Contrôle Qualité Pharmaceutique (+15 %)
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
